Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease.
Malíčková K, Ďuricová D, Bortlík M, Hind'oš M, Machková N, Hrubá V, Lukáš M, Zima T, Lukáš M. Malíčková K, et al. Among authors: hruba v. Biologicals. 2016 Jan;44(1):33-6. doi: 10.1016/j.biologicals.2015.09.005. Epub 2015 Oct 23. Biologicals. 2016. PMID: 26603635 Clinical Trial.
Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.
Farkas K, Rutka M, Golovics PA, Végh Z, Lovász BD, Nyári T, Gecse KB, Kolar M, Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, Malickova K, Bálint A, Nagy F, Bor R, Milassin Á, Szepes Z, Palatka K, Lakatos PL, Lukas M, Molnár T. Farkas K, et al. Among authors: hruba v. J Crohns Colitis. 2016 Nov;10(11):1273-1278. doi: 10.1093/ecco-jcc/jjw085. Epub 2016 Apr 21. J Crohns Colitis. 2016. PMID: 27106537 Clinical Trial.
Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.
Bálint A, Rutka M, Végh Z, Kürti Z, Gecse KB, Banai J, Bene L, Gasztonyi B, Kristóf T, Lakatos L, Miheller P, Palatka K, Patai Á, Salamon Á, Szamosi T, Szepes Z, Tóth GT, Vincze Á, Bor R, Milassin Á, Fábián A, Nagy F, Kolar M, Bortlik M, Duricova D, Hruba V, Lukas M, Mitrova K, Malickova K, Lukas M, Lakatos PL, Molnár T, Farkas K. Bálint A, et al. Among authors: hruba v. Expert Opin Drug Saf. 2017 Aug;16(8):885-890. doi: 10.1080/14740338.2017.1323330. Epub 2017 May 26. Expert Opin Drug Saf. 2017. PMID: 28504555 Free article.
Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation.
Duricova D, Dvorakova E, Hradsky O, Mitrova K, Durilova M, Kozeluhova J, Kohout P, Zarubova K, Bronsky J, Hradska N, Bronska E, Adamcova M, Machkova N, Hruba V, Bortlik M, Lukas M, Malickova K, Lukas M. Duricova D, et al. Among authors: hruba v. Inflamm Bowel Dis. 2019 Mar 14;25(4):789-796. doi: 10.1093/ibd/izy294. Inflamm Bowel Dis. 2019. PMID: 30239799 Clinical Trial.
Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort.
Bálint A, Rutka M, Kolar M, Bortlik M, Duricova D, Hruba V, Lukas M, Mitrova K, Malickova K, Lukas M, Szepes Z, Nagy F, Palatka K, Lovas S, Végh Z, Kürti Z, Csontos Á, Miheller P, Nyári T, Bor R, Milassin Á, Fábián A, Szántó K, Lakatos PL, Molnár T, Farkas K. Bálint A, et al. Among authors: hruba v. Expert Opin Biol Ther. 2018 Nov;18(11):1181-1187. doi: 10.1080/14712598.2018.1530758. Epub 2018 Oct 9. Expert Opin Biol Ther. 2018. PMID: 30277084
18 results